ABCL
AbCellera Biologics Inc.
There isn't enough reported data to score ABCL yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ABCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
ABCL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABCL PE Valuation
ABCL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ABCL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABCL's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ABCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$0.09 |
| Q2 2026 | -$0.54 | +$0.01 |
| Q1 2026 | -$0.48 | +$0.08 |
| Q4 2025 | -$0.49 | +$0.06 |
| Q3 2025 | -$0.57 | +$0.03 |
| Q2 2025 | -$0.55 | -$0.02 |
| Q1 2025 | -$0.56 | -$0.05 |
| Q4 2024 | -$0.55 | -$0.04 |
ABCL is still losing money, but less than at its worst: $0.48 per share over the past year, against $0.60 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ABCL on earnings quality, reporting a profit while its opponent remains loss making.
ABCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +19% |
| Q2 2026 | $4.1M | -76% |
| Q1 2026 | $8.3M | +96% |
| Q4 2025 | $44.9M | +788% |
| Q3 2025 | $9M | +38% |
| Q2 2025 | $17.1M | +133% |
| Q1 2025 | $4.2M | -57% |
| Q4 2024 | $5.1M | -45% |
ABCL's revenue is recovering but still below its 2022 peak: $11M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -501% | +351 points |
| Q2 2026 | -1550% | -1260 points |
| Q1 2026 | -692% | +788 points |
| Q4 2025 | -64% | +1377 points |
| Q3 2025 | -852% | +588 points |
| Q2 2025 | -290% | +986 points |
| Q1 2025 | -1480% | -928 points |
| Q4 2024 | -1441% | -721 points |
ABCL's operating margin was −501% last quarter, up 351 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ABCL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ABCL on profitability, with a higher operating margin.
ABCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.3M | +$86.8M |
| Q2 2026 | $23.8M | +$69.6M |
| Q1 2026 | -$37.4M | -$15.2M |
| Q4 2025 | -$44.6M | -$21M |
| Q3 2025 | -$61.5M | -$14.1M |
| Q2 2025 | -$45.8M | +$4.3M |
| Q1 2025 | -$22.2M | +$43.7M |
| Q4 2024 | -$23.6M | +$10.4M |
ABCL has burned cash in most quarters: −$33M over the past year, against −$153M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ABCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +12.5M shares |
| 1 year | +6.4% | +19.2M shares |
| 3 years | +9.9% | +28.6M shares |
| 5 years | +14% | +39.1M shares |
| Available history | +34% | +80.3M shares |
ABCL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ABCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.6x | Net Cash |
| Q3 2022 | -1.1x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -1.9x | Net Cash |
| Q4 2021 | -2.2x | Net Cash |
| Q4 2020 | -3.5x | Net Cash |
| Q3 2020 | -12.0x | Net Cash |
| Q2 2020 | -14.9x | Net Cash |
ABCL has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ABCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 62.7 | Neutral |
ABCL's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ABCL PE vs Healthcare Sector
| Metric | ABCL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABCL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ABCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 5.5% below |
| 20 week MA | $10.3 | 12% above |
| 50 week MA | $6.63 | 75% above |
| 100 week MA | $5.07 | 129% above |
| 200 week MA | $5.06 | 130% above |
ABCL's trend is up, with a small recent dip: it's below only its 8-week average, and 130% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ABCL on trend strength, trading above more of its moving averages.
ABCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $42.4 | -28% |
| 2021 | $42.4 | $14.9 | -65% |
| 2022 | $14.9 | $10.3 | -31% |
| 2023 | $10.3 | $5.71 | -45% |
| 2024 | $5.71 | $2.99 | -48% |
| 2025 | $2.99 | $3.58 | +20% |
| 2026 YTD | $3.58 | $11.6 | +225% |
ABCL has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.